ArticleCellular & molecular biology letters2026
METTL3-m
Article in Cellular & molecular biology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundOwing to their immunosuppressive nature, mesenchymal stem cells (MSCs)—a type of multipotent stem cell—hold considerable promise for therapeutic applications. Functioning as the primary catalytic subunit of the RNA N6-methyladenosine (m6A) methyltransferase complex, methyltransferase-like 3 (METTL3) plays extensive roles in numerous biological processes. It is hypothesized that METTL3 participates in governing the immunomodulatory functions inherent to MSCs. However, the exact mechanisms governing METTL3’s control over MSCs’ immunosuppressive capacity are poorly defined.
methodsMSCs extracted from bone marrow were transfected with lentivirus to knockdown or overexpress METTL3, while METTL3 enzyme activity was inhibited using the METTL3 inhibitor STM2457. In vitro co-culture assays and in vivo tumor models revealed that knocking down METTL3 or inhibiting its enzyme activity in MSCs weakened its inhibitory ability on T cells, while overexpressing METTL3 increased its inhibitory ability. in both concanavalin A (ConA)-induced liver injury and dextran sulfate sodium (DSS)-induced colitis models, the therapeutic benefits of MSCs against inflammatory diseases were shown to be dependent on METTL3
resultsOur findings establish METTL3 as a critical regulator of the immunosuppressive capacity of MSCs, mediated through inducible nitric oxide synthase (iNOS) expression. Mechanistic investigations revealed that METTL3 targets JAK1, STAT1, TAB1, and NFKB1 in an IGF2BP1/2-dependent fashion. This regulatory influence stems from METTL3’s ability to potentiate STAT1 and NF-κB signaling pathways. Supporting this, overexpression of METTL3 enhanced NF-κB and STAT1 activation, which consequently elevated iNOS expression.
conclusionsMETTL3 enhances MSC immunosuppression via the m6A–STAT1/NF-κB–iNOS axis, presenting a dual role: it potentiates therapeutic efficacy in inflammatory diseases but exacerbates tumor progression by impairing T-cell infiltration. Targeting METTL3 offers a strategy to optimize MSC-based therapies, though context-specific modulation is essential to balance benefits and risks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.